Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
Settings
Settings
Dynamic quotes 
OFFON

4-Traders Homepage  >  Equities  >  Nasdaq  >  Regeneron Pharmaceuticals    REGN

SummaryQuotesChartsNewsAnalysisCalendarCompanyFinancialsConsensusRevisions 
News SummaryMost relevantAll newsSector newsTweets

Regeneron shares poised for rebound: Barron's

share with twitter share with LinkedIn share with facebook
share via e-mail
0
05/07/2017 | 07:19pm CEST

Shares of Regeneron Pharmaceuticals Inc, which tumbled 32 percent in 2016, are poised for a rebound, the financial newspaper Barron's said.

A better-than-expected launch of Regeneron's skin treatment Dupixent caused shares to soar last week, the paper reported in its May 8 edition. If Dupixent usage grows faster than expected, it could take pressure off Regeneron's other drugs, including eye drug Eylea, Barron's said.

Regeneron said that 900 prescriptions had been written for Dupixent and that the number of doctors prescribing the drug had jumped by nearly 50 percent.

(Reporting by Olivia Oran; Editing by Phil Berlowitz)

share with twitter share with LinkedIn share with facebook
share via e-mail
0
Latest news on REGENERON PHARMACEUTICALS
09/21 REGENERON PHARMACEUTICALS : Important Note Regarding the September 11, 2017 Pres..
09/21 REGENERON PHARMACEUTICALS : and Sanofi Announce Positive Dupilumab Topline Resul..
09/19 SANOFI : and Regeneron Announce Positive Study Results for Dupixent in Patients ..
09/18 SANOFI : and Regeneron Announce Positive Study Results for Dupixent (dupilumab) ..
09/18 SANOFI : and Regeneron Announce Positive Study Results for Dupixent (dupilumab) ..
09/16 SANOFI : and Regeneron Announce Positive Study Results for Dupixent® (dupilumab)..
09/14 REGENERON PHARMACEUTICALS : and Sanofi Announce Cemiplimab REGN2810 Has Received..
09/14 REGENERON PHARMACEUTICALS : `s Dupixent Takes Another Step Toward Blockbuster St..
09/14 REGENERON PHARMACEUTICALS,INC. (NASD : REGN) Files An 8-K Submission of Matters ..
09/13 REGENERON PHARMACEUTICALS : Submission of Matters to a Vote of Security Holders ..
More news
News from SeekingAlpha
09/21 Esperion Therapeutics Remains Undervalued
09/19 YOUR DAILY PHARMA SCOOP : Nabriva's Further Potential, Allergan's IP Gimmick, Su..
09/19 Biotech And Pharma Stocks To Soak Up At The Bottom
09/18 Regeneron and Sanofi's Dupixent shows positive effect in dermatitis patients ..
09/18 Regeneron - Diversification Efforts Could Soon Yield Results
Financials ($)
Sales 2017 5 747 M
EBIT 2017 2 392 M
Net income 2017 1 331 M
Finance 2017 2 285 M
Yield 2017 -
P/E ratio 2017 37,72
P/E ratio 2018 34,03
EV / Sales 2017 7,67x
EV / Sales 2018 6,76x
Capitalization 46 367 M
Chart REGENERON PHARMACEUTICALS
Duration : Period :
Regeneron Pharmaceuticals Technical Analysis Chart | REGN | US75886F1075 | 4-Traders
Technical analysis trends REGENERON PHARMACEUTICALS
Short TermMid-TermLong Term
TrendsBearishNeutralBullish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 26
Average target price 496 $
Spread / Average Target 15%
EPS Revisions
Managers
NameTitle
Leonard S. Schleifer President, Chief Executive Officer & Director
P. Roy Vagelos Chairman
Robert E. Landry Chief Financial Officer & Senior VP-Finance
George Damis Yancopoulos Director & Chief Scientific Officer
Neil Stahl Executive VP-Research & Development
Sector and Competitors
1st jan.Capitalization (M$)
REGENERON PHARMACEUTICALS18.08%46 367
AMGEN27.65%135 544
CELGENE CORPORATION24.22%112 572
GILEAD SCIENCES15.37%108 744
VERTEX PHARMACEUTICALS106.41%38 136
ACTELION22.00%29 523